Heron reports Q3 2026 net revenue of $35.3M amid asset sale to CorMedix
Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, with SUSTOL sales ceasing late in the quarter. In parallel, the company entered a definitive agreement to sell substantially all assets to CorMedix Therapeutics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed